BHC

6.30

0.16% -0.010

Dopo l'orario di chiusura: 6.19 -0.11 -1.75%

Bausch Health Companies Inc (BHC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$6.31

Aprire:

$6.35

Volume 24 ore:

2.16M

Relative Volume:

1.13

Capitalizzazione di mercato:

$2.36B

Reddito:

$10.53B

Utile/perdita netta:

$-1.23B

Rapporto P/E:

-1.9409

EPS:

-3.246

Flusso di cassa netto:

$949.99M

1 W Prestazione:

+4.30%

1M Prestazione:

+10.72%

6M Prestazione:

+8.25%

1 anno Prestazione:

+4.83%

Intervallo 1D:

$6.20

$6.385

Intervallo di 1 settimana:

$5.732

$6.385

Portata 52W:

$4.33

$8.00

Bausch Health Companies Inc Stock (BHC) Company Profile

Nome

Bausch Health Companies Inc

Settore

Healthcare (1052)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

514-744-6792

Indirizzo

2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC

Dipendente

20,300

Cinguettio

Prossima data di guadagno

2026-10-28

Ultimi documenti SEC

BHC's Discussions on Twitter

Compare BHC vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BHC Bausch Health Companies Inc	6.30	2.36B	10.53B	-1.23B	949.99M	-3.246
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Barclays	Equal Weight
2024-08-02	Downgrade	Piper Sandler	Neutral → Underweight
2024-07-10	Iniziato	Raymond James	Mkt Perform
2023-09-20	Aggiornamento	Jefferies	Hold → Buy
2023-06-16	Downgrade	TD Cowen	Outperform → Market Perform
2022-07-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-07-29	Downgrade	Truist	Buy → Hold
2022-07-28	Downgrade	JP Morgan	Overweight → Neutral
2022-06-13	Ripresa	JP Morgan	Overweight
2021-03-24	Downgrade	BofA Securities	Neutral → Underperform
2021-02-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2021-01-22	Downgrade	Piper Sandler	Overweight → Neutral
2020-09-17	Aggiornamento	BofA Securities	Underperform → Neutral
2020-08-24	Reiterato	H.C. Wainwright	Buy
2020-06-17	Reiterato	H.C. Wainwright	Buy
2020-04-24	Iniziato	Citigroup	Buy
2020-04-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-01-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2020-01-22	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2019-12-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-02	Iniziato	Goldman	Neutral
2019-10-25	Iniziato	Cowen	Outperform
2019-09-12	Iniziato	Guggenheim	Buy
2019-08-15	Aggiornamento	TD Securities	Hold → Buy
2019-07-19	Iniziato	Wolfe Research	Outperform
2019-06-11	Ripresa	Barclays	Overweight
2019-05-13	Aggiornamento	JP Morgan	Underweight → Neutral
2019-03-20	Iniziato	SunTrust	Buy
2019-01-02	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-11-05	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-09-13	Aggiornamento	Piper Jaffray	Underweight → Neutral

Mostra tutto

Bausch Health Companies Inc Borsa (BHC) Ultime notizie

Oct 12, 2026

Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters

Oct 12, 2026

Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com

Oct 12, 2026

What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media

Oct 12, 2026

Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief - The Mighty 790 KFGO

Oct 12, 2026

Bausch Health study shows improved cirrhosis care adherence By Investing.com - Investing.com Canada

Oct 12, 2026

Bausch Health study shows modest gains in cirrhosis care adherence - StreetInsider

Oct 12, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway - PR Newswire

Oct 12, 2026

Bausch + Lomb Names Thomas J. Appio Interim CEO - www.tokenpost.com

Oct 12, 2026

Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider

Oct 12, 2026

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - The Globe and Mail

Oct 12, 2026

Oct 10, 2026